Oxaliplatin (OXA), 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced or metastatic gastric cancer (A/MGC)

Cavanna, Luigi; Zaniboni, Alberto; Artioli, Fabrizio; Lazzaro, Antonio; Rizzi, Anna; Mazzocchi, Maria; Bernuzzi, Patrizia; Bertè, Roberto; Bidin, L.; Palladino, M. A.

doi:10.1200/jco.2004.22.90140.4068

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, single-agent activity was reported to result in lower response rates in gastroenteric tumor patients. A regimen of 5-FU combined with oxaliplatin enhanced the effective response [10,11] . In recent years, a regimen of L-OHP combined with a high-dose folinic acid plus 5-FU for the treatment of gastric cancer has been thoroughly tested confirming its efficacy [12,13] .…”

Section: Discussionmentioning

confidence: 99%

Treatment of advanced gastric carcinoma patients with calcium folinate, a 5-fluorouracil bolus and continous infusion with 5-fluorouracil combined with oxaliplatin

Liang

Chen

Da-chao

et al. 2008

Chin. J. Clin. Oncol.

View full text Add to dashboard Cite

OBJECTIVE To examine the therapeutic effects and toxicity of high-dose-folinic acid plus a 5-fluorouracil (5-FU) bolus and continuous infusion with 5-FU combined with locally produced oxaliplatin (L-HOP)in treating advanced gastric carcinoma patients. METHODS Sixty-fi ve patients with advanced gastric carcinoma were treated with high-dose-folinic acid plus a 5-FU bolus and a 48-h continuous infusion of 5-FU combined with oxaliplatin. The eff ects of treatment and toxicity were observed. RESULTS There were 4 complete responses, 26 partial responses, 30 with no change and 5 with progressive disease. The overall effective response rate was 46.2% (30/65). The median duration was 7 months, with the main side effects including nausea and vomiting, peripheral phlebitis, alopecia, leukopenia, dental ulcers, peripheral neuritis and diarrhea. All the side eff ects were tolerated and minimal. CONCLUSION The results showed that high-dose folinic acid plus a 5-FU bolus and continuous infusion of 5-FU combined with oxaliplatin appears to be a safe and eff ective therapy for patients with advanced gastric carcinoma. This therapeutic regimen is of value for these patients.KEY WORDS: advanced gastric carinoma, calcium folinate, 5-fl uorouracil, oxaliplatin, chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of advanced gastric carcinoma patients with calcium folinate, a 5-fluorouracil bolus and continous infusion with 5-fluorouracil combined with oxaliplatin

Liang

Chen

Da-chao

et al. 2008

Chin. J. Clin. Oncol.

View full text Add to dashboard Cite

show abstract

“…Various Phase II studies have reported response rates of between 38 and 56% [109][110][111][112][113][114][115][116][117][118]. Median survival times have ranged from 8 to 11.5 months.…”

Section: Oxaliplatinmentioning

confidence: 99%

Recent developments in the systemic therapy of advanced gastroesophageal malignancies

Khamly¹,

Jefford²,

Michael³

et al. 2006

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Cancers of the upper gastrointestinal tract are a common cause of worldwide morbidity and mortality. The prognosis for patients with these cancers remains poor and only a minority of patients are cured. Systemic therapy has been used to treat patients with advanced disease but outcomes have not improved dramatically in the past few decades. Newer, more effective agents are desperately needed, and agents such as the taxanes (docetaxel and paclitaxel), irinotecan, oxaliplatin and capecitabine have recently shown some promise. In addition, molecularly targeted, non-cytotoxic therapies are being evaluated with the hope of improving the available therapeutic options. This article reviews the current clinical data regarding systemic therapy for patients with advanced upper gastrointestinal malignancies.

show abstract

Oxaliplatin (OXA), 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced or metastatic gastric cancer (A/MGC)

Cited by 2 publications

References 0 publications

Treatment of advanced gastric carcinoma patients with calcium folinate, a 5-fluorouracil bolus and continous infusion with 5-fluorouracil combined with oxaliplatin

Treatment of advanced gastric carcinoma patients with calcium folinate, a 5-fluorouracil bolus and continous infusion with 5-fluorouracil combined with oxaliplatin

Recent developments in the systemic therapy of advanced gastroesophageal malignancies

Contact Info

Product

Resources

About